Bissonnette R, Gold LS, Kircik L, Simpson EL, et al. Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. J Am Acad Dermatol 2025 May 16:S0190-9622(25)02130.
PMID: 40383273